Recent Posts

• Gustave Roussy and LXRepair announce a partnership for personalized radiotherapy of cancer
• Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners
• Amolyt Pharma to Host Key Opinion Leader Webinar and Discuss Results of Phase I Clinical Trial of AZP-3601 on Friday, October 1st at 10:00am ET
• Amolyt Pharma Exercises Option to License Optimized Acromegaly Drug Candidate from PeptiDream as it Continues to Build its Rare Endocrine Pipeline.
• Theranexus and Beyond Batten Disease Foundation (BBDF) win us Investigational New Drug (IND) approval to start clinical development of BBDF 101